Skip to main content

Tegal Gets Shareholder OK to Change Name to CollabRx

NEW YORK (GenomeWeb News) – Tegal said after the close of the market yesterday that it has received approval from its shareholders to change the name of the firm to CollabRx.

The name change comes a couple of months after Tegal completed its purchase of genomics data analysis firm CollabRx for an undisclosed amount. At the time, Tegal had said that it would ask its shareholders to approve the name change.

As of tomorrow, the firm's shares will trade on the Nasdaq under the ticker symbol CLRX.

Tegal develops new and emerging technologies with a current focus on technologies in the medical device and healthcare segments. CollabRx offers cloud-based systems to inform healthcare decision-making using genomics-based medicine.

Each firm's CEO — Thomas Mika of Tegal and James Karis of CollabRx — are serving as co-CEOs of the San Francisco-based firm. Mika continues to serve as chairman.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.